Global patterns of prescription pain medication usage in disorders of gut–brain interactions
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/257244 |
Resumo: | Background: Forty percent of individuals globally meet Rome IV criteria for a disorder of gut– brain interaction (DGBI). The global burden of pain across these disorders has not been characterized.Methods: Our study included 54,127 respondents from the 26 Internet survey coun-tries. Prescription pain medication usage was selected as the proxy for pain. The associations between prescription pain medications and the environmental, sociode-mographic, psychosocial, and DGBI diagnosis variables were investigated using the multivariate generalized robust Poisson regression model.Key Results: Respondents with DGBI used prescription pain medications at higher rates than those without a DGBI diagnosis with pooled prevalence rate of 14.8% (95% confidence interval [CI], 14.4– 15.3%), varying by country from 6.8% to 25.7%. The pooled prevalence ratio of prescription pain medication usage in respondents with and without DGBI was 2.2 (95% CI: 2.1– 2.4). Factors associated with higher preva -lence of pain medication usage among respondents with a DGBI diagnosis included living in a small community, increased anxiety, depression or somatization, increased stress concern or embarrassment about bowel functioning and having more than one anatomic DGBI diagnosis.Conclusion: 14.8% of patients globally with at least one diagnosis of DGBI were on prescription pain medications with wide geographic variation, about twice as many as their counterparts without a diagnosis of DGBI. Environmental, sociodemographic, and individual factors may influence clinicians to consider personalized, multimodal approaches to address pain in patients with DGBI. |
id |
UFRGS-2_9934b08c8a007b049b9fa88963f34e85 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/257244 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Luo, YuyingCamey, Suzi AlvesBangdiwala, ShrikantPalsson, Olafur S.Sperber, Ami D.Keefer, Laurie A.2023-04-19T03:26:55Z20231365-2982http://hdl.handle.net/10183/257244001159132Background: Forty percent of individuals globally meet Rome IV criteria for a disorder of gut– brain interaction (DGBI). The global burden of pain across these disorders has not been characterized.Methods: Our study included 54,127 respondents from the 26 Internet survey coun-tries. Prescription pain medication usage was selected as the proxy for pain. The associations between prescription pain medications and the environmental, sociode-mographic, psychosocial, and DGBI diagnosis variables were investigated using the multivariate generalized robust Poisson regression model.Key Results: Respondents with DGBI used prescription pain medications at higher rates than those without a DGBI diagnosis with pooled prevalence rate of 14.8% (95% confidence interval [CI], 14.4– 15.3%), varying by country from 6.8% to 25.7%. The pooled prevalence ratio of prescription pain medication usage in respondents with and without DGBI was 2.2 (95% CI: 2.1– 2.4). Factors associated with higher preva -lence of pain medication usage among respondents with a DGBI diagnosis included living in a small community, increased anxiety, depression or somatization, increased stress concern or embarrassment about bowel functioning and having more than one anatomic DGBI diagnosis.Conclusion: 14.8% of patients globally with at least one diagnosis of DGBI were on prescription pain medications with wide geographic variation, about twice as many as their counterparts without a diagnosis of DGBI. Environmental, sociodemographic, and individual factors may influence clinicians to consider personalized, multimodal approaches to address pain in patients with DGBI.application/pdfengNeurogastroenterology and Motility. Hoboken. Vol. 35, n. 1 (2023), e14457DorMedicamentosDisorders of gut-brain interactionPainPrescription pain medicationsGlobal patterns of prescription pain medication usage in disorders of gut–brain interactionsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001159132.pdf.txt001159132.pdf.txtExtracted Texttext/plain42215http://www.lume.ufrgs.br/bitstream/10183/257244/2/001159132.pdf.txt58de06ab349d8f6061fc2cf232012921MD52ORIGINAL001159132.pdfTexto completo (inglês)application/pdf744266http://www.lume.ufrgs.br/bitstream/10183/257244/1/001159132.pdf9cea812b7e35afa6aada37c2a4959213MD5110183/2572442023-04-20 03:22:45.786509oai:www.lume.ufrgs.br:10183/257244Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-04-20T06:22:45Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
title |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
spellingShingle |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions Luo, Yuying Dor Medicamentos Disorders of gut-brain interaction Pain Prescription pain medications |
title_short |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
title_full |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
title_fullStr |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
title_full_unstemmed |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
title_sort |
Global patterns of prescription pain medication usage in disorders of gut–brain interactions |
author |
Luo, Yuying |
author_facet |
Luo, Yuying Camey, Suzi Alves Bangdiwala, Shrikant Palsson, Olafur S. Sperber, Ami D. Keefer, Laurie A. |
author_role |
author |
author2 |
Camey, Suzi Alves Bangdiwala, Shrikant Palsson, Olafur S. Sperber, Ami D. Keefer, Laurie A. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Luo, Yuying Camey, Suzi Alves Bangdiwala, Shrikant Palsson, Olafur S. Sperber, Ami D. Keefer, Laurie A. |
dc.subject.por.fl_str_mv |
Dor Medicamentos |
topic |
Dor Medicamentos Disorders of gut-brain interaction Pain Prescription pain medications |
dc.subject.eng.fl_str_mv |
Disorders of gut-brain interaction Pain Prescription pain medications |
description |
Background: Forty percent of individuals globally meet Rome IV criteria for a disorder of gut– brain interaction (DGBI). The global burden of pain across these disorders has not been characterized.Methods: Our study included 54,127 respondents from the 26 Internet survey coun-tries. Prescription pain medication usage was selected as the proxy for pain. The associations between prescription pain medications and the environmental, sociode-mographic, psychosocial, and DGBI diagnosis variables were investigated using the multivariate generalized robust Poisson regression model.Key Results: Respondents with DGBI used prescription pain medications at higher rates than those without a DGBI diagnosis with pooled prevalence rate of 14.8% (95% confidence interval [CI], 14.4– 15.3%), varying by country from 6.8% to 25.7%. The pooled prevalence ratio of prescription pain medication usage in respondents with and without DGBI was 2.2 (95% CI: 2.1– 2.4). Factors associated with higher preva -lence of pain medication usage among respondents with a DGBI diagnosis included living in a small community, increased anxiety, depression or somatization, increased stress concern or embarrassment about bowel functioning and having more than one anatomic DGBI diagnosis.Conclusion: 14.8% of patients globally with at least one diagnosis of DGBI were on prescription pain medications with wide geographic variation, about twice as many as their counterparts without a diagnosis of DGBI. Environmental, sociodemographic, and individual factors may influence clinicians to consider personalized, multimodal approaches to address pain in patients with DGBI. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-04-19T03:26:55Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/257244 |
dc.identifier.issn.pt_BR.fl_str_mv |
1365-2982 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001159132 |
identifier_str_mv |
1365-2982 001159132 |
url |
http://hdl.handle.net/10183/257244 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Neurogastroenterology and Motility. Hoboken. Vol. 35, n. 1 (2023), e14457 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/257244/2/001159132.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/257244/1/001159132.pdf |
bitstream.checksum.fl_str_mv |
58de06ab349d8f6061fc2cf232012921 9cea812b7e35afa6aada37c2a4959213 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225086685937664 |